← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
International Aids Vaccine Initiative
New York, NY
$59,836,958
Total funding
25
Grants
Funding over time
peak $12.2M · FY2009–25$20M$15M$10M$5M$0
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$59,836,958 · 25
By mechanism
N01$33,701,257 · 6
P01$12,209,586 · 6
U19$9,278,767 · 7
R01$2,029,852 · 1
R61$1,336,253 · 1
R33$700,469 · 1
Investigators at International Aids Vaccine Initiative
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Emerging Leaders
6–10 yrs in
Largest grants
cGMP Manufacture, Fill-Finish, Release, Analytical and Stability Testing and Stability Program of a Nanoparticle Based HIV Envelope Vaccine$3,974,723
N01 · FY2022 · AI
cGMP Manufacture, Fill-Finish, Release, Analytical and Stability Testing and Stability Program of a Nanoparticle Based HIV Envelope Vaccine$3,358,279
N01 · FY2025 · AI
Task 02: Manufacture of Influenza for Human Challenge Clinical Trials$2,789,946
N01 · FY2018 · AI
Pushing the envelope: Optimizing vaccine display of flexibly linked HIV Env trimer immunogens$2,635,377
P01 · FY2018 · AI
Pushing the envelope: Optimizing vaccine display of flexibly linked HIV Env trimer immunogens$2,525,443
P01 · FY2016 · AI
Interplay of B cells and HIV Leading to Broad Neutralizing Antibody Responses$2,452,497
U19 · FY2012 · AI
Pushing the envelope: Optimizing vaccine display of flexibly linked HIV Env trimer immunogens$2,445,841
P01 · FY2017 · AI
Pushing the envelope: Optimizing vaccine display of flexibly linked HIV Env trimer immunogens$2,353,868
P01 · FY2019 · AI
Interplay of B cells and HIV Leading to Broad Neutralizing Antibody Responses$2,282,525
U19 · FY2013 · AI
Pushing the envelope: Optimizing vaccine display of flexibly linked HIV Env trimer immunogens$2,249,057
P01 · FY2020 · AI
Task V32: Manufacture of Influenza Virus Human Challenge Material for Phase I/II Clinical Testing$2,131,382
N01 · FY2024 · AI
Process Development for Cell Culture, Upstream and Downstream Process in Production of HIV-1 Biomolecules$1,726,828
N01 · FY2019 · AI
Nanoparticle-based development for HIV-1 biomolecule delivery$1,595,794
N01 · FY2021 · AI
Interplay of B cells and HIV Leading to Broad Neutralizing Antibody Responses$1,560,717
U19 · FY2010 · AI
Interplay of B cells and HIV Leading to Broad Neutralizing Antibody Responses$1,503,156
U19 · FY2011 · AI
Task V32: Manufacturing and Characterization Services for Universal Influenza Vaccines.$1,494,007
N01 · FY2023 · AI
Interplay of B cells and HIV Leading to Broad Neutralizing Antibody Responses$1,487,455
U19 · FY2014 · AI
Evolution of Broadly Neutralizing Responses Tracked in Monoclonal Abs$1,345,887
U19 · FY2013 · AI
Evolution of Broadly Neutralizing Responses Tracked in Monoclonal Abs$1,332,233
U19 · FY2012 · AI
Task V03: Product Development Plans$1,297,428
N01 · FY2019 · AI